2000DalSpace (Dalhousie University)Requires access

The relative potency of testosterone and dihydrotestosterone in the rat ventral prostate: Role of 5alpha-reductase.

A. Stuart Wright

Open publisher page 0 citations

Abstract

Testosterone (T), the major circulating androgen, must be converted to dihydrotestosterone (DHT) by the enzyme 5alpha-reductase (5alpha-R) for maximal activity in the prostate. Based on its higher affinity for the androgen receptor, its high intraprostatic concentration and the observation that men with congenital 5alpha-R deficiency have small prostates, DHT was considered to be the only active androgen in the prostate. In both rats and men, administration of 5alpha-R inhibitors such as finasteride results in prostate shrinkage but not to the same extent as castration. The most probable reason is the reciprocal rise in intraprostatic T that accompanies the decrease in DHT on 5alpha-R inhibition. The objective of the studies presented here was to investigate the relative potencies of T and DHT in prevention of rat ventral prostate regression and in regrowth.

About this research paper

What this paper is about

Testosterone (T), the major circulating androgen, must be converted to dihydrotestosterone (DHT) by the enzyme 5alpha-reductase (5alpha-R) for maximal activity in the prostate. Based on its higher affinity for the androgen receptor, its high intraprostatic concentration and the observation that men with congenital 5alpha-R deficiency have small prostates, DHT was considered to be the only active androgen in the prostate. In both rats and men, administration of 5alpha-R inhibitors such as finasteride results in prostate shrinkage but not to the same extent as castration. The most probable reason is the reciprocal rise in intraprostatic T that accompanies the decrease in DHT on 5alpha-R inhibition. The objective of the studies presented here was to investigate the relative potencies of T and DHT in prevention of rat ventral prostate regression and in regrowth.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Testosterone (T), the major circulating androgen, must be converted to dihydrotestosterone (DHT) by the enzyme 5alpha-reductase (5alpha-R) for maximal activity in the prostate. Based on its higher affinity for the androgen receptor, its high intraprostatic concentration and the observation that men with congenital 5alpha-R deficiency have small prostates, DHT was considered to be the only active androgen in the prostate. In both rats and men, administration of 5alpha-R inhibitors such as finasteride results in prostate shrinkage but not to the same extent as castration. The most probable reason is the reciprocal rise in intraprostatic T that accompanies the decrease in DHT on 5alpha-R inhibition. The objective of the studies presented here was to investigate the relative potencies of T and DHT in prevention of rat ventral prostate regression and in regrowth.

Key concepts: Finasteride, Dihydrotestosterone, Testosterone (patch), Endocrinology, Prostate, Internal medicine, Androgen, Androgen receptor

Related papers

Back to paper searchBrowse research topicsOriginal source
The relative potency of testosterone and dihydrotestosterone in the rat ventral prostate: Role of 5alpha-reductase. — Research Paper | ScholarLens